Arbutus Biopharma

442 articles about Arbutus Biopharma

• Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™

  6/26/2021

  Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, announced the presentation of five abstracts at the European Association for the Study of the Liver International Liver CongressTM.

• Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June

  6/2/2021

  Conference Call and Webcast to discuss the new data being presented at EASL  scheduled for 8:00 AM ET, Monday, June 28, 2021

• Arbutus to Participate in Upcoming Investor Conferences - May 26, 2021

  5/26/2021

  Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus infection, as well as therapies to treat coronaviruses, announced that the Company will participate in the following upcoming investor conferences

• Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update

  5/5/2021

  AB-729, Arbutus’ proprietary subcutaneously delivered RNAi agent, continues to demonstrate robust and continuous declines in hepatitis B surface antigen (HBsAg) in subjects with chronic hepatitis B (HBV) with favorable safety and tolerability data Additional data from the ongoing Phase 1a/1b clinical trial of AB-729, including 60 mg multi-dose data (dosing interval every 4 and 8 weeks) and 90 mg multi-dose data (dosing interval every 8 weeks), expected in 2Q/2021

• Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update

  4/28/2021

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its first quarter 2021 financial results and corporate update for Wednesday, May 5, 2021.

• Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement

  4/1/2021

  Collaboration formed to accelerate the discovery of novel oral inhibitors targeting the SARS-CoV-2 nsp5 main protease for the treatment of COVID-19 and potential future coronavirus outbreaks

• Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection

  3/16/2021

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has received regulatory approval to initiate a Phase 1a/1b clinical trial with AB-836, its proprietary oral capsid inhibitor for the treatment of HBV infection.

• Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update

  3/4/2021

  Arbutus Biopharma today reports its fourth quarter and year-end 2020 financial results and provides a corporate update.

• Arbutus to Participate at H.C. Wainwright Global Life Sciences Conference

  3/2/2021

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference held virtually from March 9-10, 2021.

• Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus

  2/26/2021

  Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS) today announced the initiation of a Phase 2 clinical trial of Assembly Bio’s investigational hepatitis B virus (HBV) core inhibitor candidate

• Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update

  2/22/2021

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that it has scheduled its fourth quarter and year end 2020 financial results and corporate update for Thursday, March 4, 2021.

• Arbutus Announces 2021 Corporate Objectives and Provides Financial Update

  1/25/2021

  Arbutus Biopharma Corporation today announced its 2021 corporate objectives and provided a financial update.

• Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference

  1/4/2021

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at the H.C. Wainwright BioConnect 2021 Conference taking place from January 11 – 14, 2021. Arbutus Fireside Chat Pr

• Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects

  12/10/2020

  Arbutus Biopharma Corporation today announced additional clinical data from an ongoing Phase 1a/1b clinical trial (AB-729-001) with AB-729, its proprietary GalNAc delivered RNAi compound.

• Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects

  11/16/2020

  Results support advancement into Phase 2 combination clinical trialswith AB-729 dosing as infrequently as every 8 or 12 weeks

• Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting

  11/15/2020

  Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau, suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted

• Arbutus to Present at Jefferies Virtual London Healthcare Conference - Nov 10, 2020

  11/10/2020

  Arbutus Biopharma Corporation announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 12:35 pm EST.

• Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update

  11/5/2020

  Results from an ongoing Phase 1a/1b clinical trial for Arbutus’ AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus (HBV) infection, to be presented at the upcoming American Association for the Study of Liver Disease (AASLD) Conference

• Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference

  9/28/2020

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today announced that the Company will participate in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on Monday, October 5, 2020 at 1:00 pm ET. Arbutus Fireside Chat

• Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg

  9/15/2020

  Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection as well as therapies to treat coronaviruses (including COVID-19), today reports continued positive data from an ongoing Phase 1a/1b clinical trial (AB-7